Beam Therapeutics (BEAM)

• Market cap: $2.52B
• 1 day: -8.18%
• 5 days: 4.03%
• 1 month: 24.05%
• 3 months: 29.05%
• 6 months: 19.38%
• Year to date: 23.20%
• 1 year: -4.19%
• 5 years: 16.63%
• 10 years: 62.29%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Employees: 374

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

81% more call options, than puts

Call options by funds: $6.97M | Put options by funds: $3.86M

54% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 24

25% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 65

4% more funds holding

Funds holding: 221 [Q3] → 230 (+9) [Q4]

1.69% more ownership

Funds ownership: 96.67% [Q3] → 98.36% (+1.69%) [Q4]

4% more capital invested

Capital invested by funds: $1.95B [Q3] → $2.02B (+$69.5M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $80 163% upside
• Avg. target: $80 163% upside
• High target: $80 163% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick Trucchio 43% 1-year accuracy 76 / 175 met price target

163% upside $80

Buy Reiterated

3 Feb 2025